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Abstract 23 
Background 24 
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyrimidine (PhIP), one of the most 25 
abundant heterocyclic aromatic amines (HAA) formed by cooking meat at high 26 
temperatures, may modify humans and rodents through the metabolic process prior to 27 
affecting nervous system development. in humans and rodents may be modified by 28 
metabolic processes and then affecting nervous system development. 29 
Methods 30 
In this paper, PhIP was used to prepare a chicken embryo model with abnormal 31 
embryonic nervous system defects. Sulforaphane (SFN) is a derivative of a 32 
glucosinolate, which is abundant in cruciferous vegetables, and can pass through the 33 
placental barrier. Moreover, SFN has antioxidant and anti-apoptotic functions and is 34 
considered as a bioactive antioxidant with significant neuroprotective effects. 35 
Nano-sulforaphane (Nano-SFN, Sulforaphane nanoparticles) was prepared by 36 
self-assembly using biocompatible, biodegradable methoxy polyethylene glycol 37 
5000-b-polyglutamic acid 10000 (mPEG5K-PGA10K) as the substrate, to explore the 38 
new application of Nano-SFN and its modified compounds as leading compounds in 39 
protecting against the abnormal development of the embryonic nervous system. 40 
Results 41 
The results show that Nano-SFN could protect against PhIP-induced central 42 
nervous system (CNS, derived from neural tube) and peripheral nervous system (PNS, 43 
derived from neural crest cells, NCCs) defects and neural tube defects (NTDs), and 44 
increase the embryo survival rate. 45 
Conclusions 46 
This study indicates that Nano-SFN can effectively alleviate the developmental 47 
defects of embryonic nervous system induced by PhIP in the microenvironment and 48 
has a protective effect on embryonic development. It not only helps with expanding 49 
the application of SFN and improving its medicinal value, but also provides a 50 
possibility of SFN being developed as a novel drug for neuroprotection. 51 
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1. Introduction 57 
Birth defects or congenital anomalies include all structural and functional 58 
alterations in embryonic or fetal development resulting from genetic, environmental 59 
or unknown causes. Risk factors include advanced maternal and paternal ages, 60 
parental consanguinity and exposure to teratogenic agents (Oliveira et al., 2011). 61 
Congenital disease of the nervous system is the main type of birth defect 62 
(Mumpe-Mwanja et al., 2019). The nervous system includes the CNS and PNS, which 63 
are derived from the neural tube and NCCs of the embryo (Lukacs et al., 2019; 64 
Wilson et al., 2004). The neural system is one of the earliest systems to begin 65 
developing, during the 1st–8th weeks of embryonic development (teratogenic 66 
sensitive period). Embryonic cells move and combine to form the primordia of organs, 67 
which are especially sensitive to teratogenic factors (Hill, 2007; Sadler, 2017). 68 
Common teratogenic factors related to the development of the nervous system, 69 
such as alcohol consumption and smoking, have attracted wide attention (de la Monte 70 
et al., 2014; Meng et al., 2018), while teratogenic factors such as PhIP, identified as 71 
the most abundant heterocyclic amine produced in common cooking procedures 72 
(Keum et al., 2005), can affect early embryonic development, leading to abnormal 73 
development of the nervous system (Cruz-Hernandez et al., 2018; Griggs et al., 2014). 74 
Conventional toxicological studies of PhIP have focused on DNA damage (Bellamri 75 
et al., 2018; Hoelzl et al., 2008), carcinogenesis and oxidative damage (Griggs et al., 76 
2014; Klewicka et al., 2012). However, exposure to PhIP during pregnancy and 77 
nursing may result in transference to fetuses and infants, plus, may be a critical risk 78 
factor for the generation of mammary carcinomas (Brittebo et al., 1994; Hasegawa et 79 
al., 1995). Knowledge on the toxicity of PhIP to the early neural system and candidate 80 
drugs to prevent it is still limited. 81 
SFN is a dietary phytochemical that is abundant in cruciferous plants (Keum et al., 82 
2005). It is regarded as a food, dietary supplement or medicine with low toxicity and 83 
is well tolerated by humans (Fahey et al., 2013; Fahey et al., 2012). SFN can protect 84 
cells from DNA damage (Russo et al., 2018) and is a potent antioxidant 85 
(Negrette-Guzman, 2019; Negrette-Guzman et al., 2013), which inhibits oxidative 86 
damage caused by various factors in neurons, glial cells, microglia and astrocytes 87 
(Danilov et al., 2009; Greco et al., 2010; Hong et al., 2005; Innamorato et al., 2008; 88 
Kraft et al., 2004; Soriano et al., 2008). In our previous study, we found that 5–10μM 89 
SFN significantly rescued ethanol-suppressed angiogenesis in chick embryos (G. 90 
Wang et al., 2018). Nano-sized medicine, in comparison with conventional medicine, 91 
leads to increased active concentrations and bioavailability (Balakumar et al., 2013). 92 
Nano-SFN could be prepared by a self-assembly method using biocompatible, 93 
biodegradable methoxy polyethylene glycol 5000-b-polyglutamic acid 10000 94 
(mPEG5K-PGA10K) as the substrate (Jiang et al., 2018; Xiao et al., 2013; Yang et al., 95 
2019; Zhang et al., 2016). Thus, it was worth determining whether or not Nano-SFN 96 
could be a candidate drug for protection against the PhIP-induced abnormal 97 
development of the nervous system. 98 
Both PhIP and nanoparticles can cross the placental barrier and enter the fetus 99 
from the external environment (Keum et al., 2005; Muoth et al., 2016). Therefore, we 100 
employed the chick embryo to investigate the neurodevelopmental toxicity of PhIP 101 
and the protective effects of Nano-SFN in this model induced by a PhIP 102 
microenvironment. The purpose was to develop a new type of Nano-SFN for the 103 
protection of embryonic development, which would not only expand the application 104 
of SFN and improves its practical value but also assist with the development of novel 105 
drugs, for example, for those with Nano-SFN as leading compounds. Through 106 
structural modification or reconstruction, it is expected to be possible to further 107 
increase its bioactivity or reduce its side effects. 108 
 109 
 110 
2. Materials and methods 111 
2.1. Preparation of Nano-SFN 112 
Based on previous work in this field (Jiang et al., 2018; Xiao et al., 2013; Yang et 113 
al., 2019; Zhang et al., 2016), here, we describe for the first time the process of the 114 
encapsulation of 10μg/μl SFN into 0.05μg/μl mPEG5K-PGA10K by self-assembly. 115 
The SFN and mPEG5K-PGA10K were dissolved in pure dimethyl sulfoxide (DMSO) 116 
and sodium lactate Ringer's solution (LR), respectively. After 10 minutes, 117 
mPEG5K-PGA10K was gently dropped into the SFN–DMSO solution on a magnetic 118 
stirrer to ensure the supersaturation of the SFN solution. Then, the mixture was 119 
ultrasonicated for 30 minutes to accelerate the intermolecular interactions, and the 120 
solution was placed in a dark room at 4 °C overnight. Next, the solution was 121 
super-centrifuged for 20 minutes at 21380g, the supernatant was removed, and the 122 
precipitate was washed with LR; this step was repeated 5 times. Afterwards, the 123 
mixture was treated with ultrasound for 30 minutes to immobilize the molecular 124 
interactions (Figure 1). The content of free drugs in the supernatant was determined 125 
by high performance liquid chromatography (HPLC), and the drug encapsulation 126 
efficiency was 23.02% ± 2.7%.  127 
 128 
Figure 1 Schematic representation of the procedure of Nano-SFN synthesis. 129 
 130 
2.2. Characterization of Nano-SFN 131 
The SFN was purchased from Sigma (142825-10-3). mPEG5K-PGA10K was 132 
purchased from Xi'an Ruixi Biotechnology Co., Ltd. (R-PL1236-15K). SFN was 133 
packaged into mPEG5K-PGA10K by self-assembly to make Nano-SFN with a 134 
concentration of 5μM. The effective Nano-SFN dimensions and their size 135 
distributions were measured using a transmission electron microscope (TEM; 136 
TECNA12, FEI, USA). Additionally, the zeta potential of the Nano-SFN in Milli-Q 137 
water was determined by dynamic light scattering (DLS) using the Zetasizer Nano ZS 138 
instrument (Malvern Instruments Ltd, UK). 139 
 140 
2.3. The zeta potential analyzer 141 
The zeta potential of the Nano-SFN was determined by dynamic light scattering 142 
(DLS) using the Zetasizer Nano ZS instrument (Malvern Instruments Ltd, UK). The 143 
zeta potential analyzer was used to determine the nanoscale characteristics of the 144 
Nano-SFN, and the particle size distribution of the diluted nanoparticles was analyzed 145 
with a laser particle size distribution analyzer. 146 
 147 
2.4. Early chick (EC) culture 148 
Fertilized leghorn eggs were acquired from the Avian Farm of South China 149 
Agricultural University (Guangzhou, China). The fertilized eggs were incubated in a 150 
humidified incubator (Yiheng Instruments, Shanghai, China) set at 38 °C and 70% 151 
humidity until the chick embryos reached the desired developmental stage. 152 
The early chick (EC) culture (Chapman SC., 2001) method was adopted to 153 
cultivate early chicken embryos, and the chicken embryos were divided into a control 154 
group (0.1% DMSO), 20μM PhIP group, 100μM PhIP group, 200μM PhIP group, 155 
300μM PhIP group and 200μM PhIP + 5μM Nano-SFN group (n = 100 per group). 156 
The embryos were cultured from HH0 stage and treated from the beginning of the 157 
culture with the drugs mixed in the medium. 158 
 159 
2.5. Immunofluorescent staining 160 
The chicken embryos were harvested after incubation and fixed in 4% PFA 161 
overnight at 4 °C. The embryos were blocked with 10% Normal Goat Serum (SB Cat. 162 
No. 0060-01) and incubated with the following primary antibodies at 4 °C overnight 163 
on a shaker: HNK-1 (1:500, Sigma, USA), PAX7 (1:100, DSHB, USA), AP2α (1:100, 164 
Cell Signaling Technology, USA), Phospho-Histone H3 (pHH3, 1:200, Cell Signaling 165 
Technology, USA), neurofilament (NF, 1:200, Invitrogen Antibodies, USA) and 166 
cleaved-Caspase3 (c-Caspase3, 1:200, Cell Signaling Technology, USA). After 167 
extensive rinsing in PBST (0.1% Tween-20), the embryos were incubated with the 168 
corresponding Alexa Fluor 555 or 488 secondary antibody (1:1000, Invitrogen, USA) 169 
at 4 °C overnight on a shaker. The embryos were later counterstained with DAPI 170 
(1:1000, Invitrogen, USA) at room temperature for 2 hours. 171 
 172 
2.6. Fluorescence microscopy photographs 173 
After immunofluorescent staining, the whole-mount embryos and the regions of 174 
interest were photographed using a stereoscope fluorescence microscope (Olympus 175 
MVX10) with imaging software (Image-Pro Plus 7.0). The embryos were then 176 
sectioned into 10µm-thick slices using a cryostat microtome (Leica CM1900, 177 
Germany) and photographed using an epi-fluorescent microscope (Olympus IX51, 178 
Leica DM 4000B) at 200x or 400x magnification with the Olympus software package 179 
Leica CW4000 FISH. 180 
 181 
2.7. Data analysis 182 
We used Image-Pro Plus 7.0 to quantify the HNK1+ area, measuring the HNK1+ 183 
staining and cell migration; NF+, c-Caspase3+ and pHH3+ cells were manually 184 
counted in the DAPI and NF or c-Caspase3 or pHH3 merged images. All the 185 
experimental data analyses and statistical charts were generated using the SPSS 13.0 186 
statistical software. The results are presented as the mean values (Mean ± SEM). 187 
Statistical significance was assessed by one-way ANOVA and Tukey’s multiple 188 
comparisons test. P < 0.05 was considered to be statistically significant. 189 
 190 
 191 
3. Result 192 
3.1. Characterization of Nano-SFN 193 
The surface charges of nanomaterials play a very decisive role, especially in 194 
electrocatalysis. A zeta potential analyzer was used to determine the characteristics of 195 
the prepared Nano-SFN. At pH 7.4, Nano-SFN had a zeta potential (ZP) of −7.21 mV 196 
± 1.3 mV and a polydispersity index (PDI) of 0.430 ± 0.095 (Figure 2A-B). The 197 
alternative nanoparticles were used to analyze their distribution using a laser particle 198 
size distribution measuring instrument, and the particle size was observed to be 195 ± 199 
32 nm (Figure 2A-B). The morphological sizes of Nano-SFN were observed by TEM 200 
(Figure 2C), the figure showed a nearly spherical shape and uniformly distributed size 201 
for the SFN nanoparticles. 202 
 203 
Figure 2 Nanoscale characterization of Nano-SFN. (A) The ZP and PDI of 204 
Nano-SFN were determined using a zeta potential analyzer. (B) Analysis of the 205 
particle size distribution of Nano-SFN using a laser particle size distribution 206 
measuring instrument. d.nm: Diameter (nm) (C) TEM image of Nano-SFN; the scale 207 
bars are shown in the figure. Red dotted squares showed the enlarged regions of the 208 
left and middle TEM micrographs. 209 
 210 
3.2. Nano-SFN reduced PhIP-induced embryonic death and NTDs 211 
To investigate the effects of different experimental concentrations of PhIP on 212 
neurotoxicity and embryonic survival, chick embryos were first incubated with 0.1% 213 
DMSO (Control); 20μM, 100μM, 200μM, or 300μM PhIP; or 200μM PhIP + 5μM 214 
Nano-SFN for 36 h in early chick (EC) culture. The previously study showed that 0.1% 215 
DMSO did not affect the embryo development (Gao, L.R et al., 2016), we also tested 216 
the effects of the packaging materials (mPEG5K-PGA10K) on the development of 217 
chicken embryos, the results proved that there was no significant negative effect on 218 
the mortality and length of chick embryos (Supplementary Figure 1).  219 
PAX7 expression is restricted to the dorsal half of the neural tube, as Figure 3A 220 
shows. The embryo could not grow normally, and there is no obvious fluorescence, 221 
indicating that they were dead embryos. While the normal embryos showed normal 222 
closure of the neural tube in the head and trunk, neural tube malformation could be 223 
observed in the PhIP-treated groups—the failure of neural tube closure—according to 224 
PAX7 immunofluorescence (Figure 3B, indicated by white arrow), the failure of 225 
neural tube closure is a severe birth defects of the CNS, namely NTDs. The mortality 226 
rates and neural tube malformation rates were increased in the PhIP-treated embryos 227 
in a dose-dependent manner and could be reversed by the Nano-SFN. The mortality 228 
rates were 0% for the Control, 8% with 20μM PhIP, 20.17% with 100μM PhIP, 53.41% 229 
with 200μM PhIP, 85% with 300μM PhIP, and 7% with 200μM PhIP + 5μM 230 
Nano-SFN. The neural tube malformation rates were 0% for the Control, 5% with 231 
20μM PhIP, 14.29% with 100μM PhIP, 35.80% with 200μM PhIP, 14% with 300μM 232 
PhIP, and 6% with 200μM PhIP + 5μM Nano-SFN (Figure 3C). 233 
 234 
Supplementary Figure 1 The effects of MPEG5K-PGA10K on the developmental 235 
chicken embryos. (A) Representative images of chicken embryos which were treated 236 
in 0.1 % DMSO or MPEG5K-PGA10K for 0, 18, 24 and 36 hours (n = 10 per group). 237 
(B) Bar chart showing the mortality rates of chick embryos. (C) Bar chart showing the 238 
length of chick embryos for various time (hours). Scale bars = 400µm (A). 239 
 240 
 241 
Figure 3 Nano-SFN reduced PhIP-induced embryonic death and NTDs. (A) 242 
Immunofluorescence of PAX7 in chicken embryos at stage HH10 in the different 243 
treatment groups (n = 10 per group). (B) Immunofluorescence of PAX7 in the heads 244 
and trunks of the chick embryos. The white arrows indicate neural tube malformations 245 
and neural tube closure defects. (C) Bar chart showing the difference in the HH10 246 
chicken embryo mortality and neural tube malformation rates among the different 247 
treatment groups. Scale bars = 500µm (A) and 200µm (B). 248 
 249 
3.3. Nano-SFN efficiently reversed PhIP-inhibited neural cell differentiation in the 250 
neural tube 251 
To investigate whether Nano-SFN played an active role in rescuing PhIP-induced 252 
suppression in neurogenesis, we implemented immunofluorescence staining with an 253 
NF antibody (Figure 4A). We observed that NF expression in the neural tubes 254 
(indicated by arrows) of the HH10 chick embryos was suppressed by 200μM PhIP but 255 
dramatically recovered after the administration of 5μM Nano-SFN (Control = 23.99 ± 256 
5.21; 200μM PhIP = 4.85 ± 1.96; 200μM PhIP + 5μM Nano-SFN = 20.22 ± 7.22; 257 
Figure 4B). The experiment confirmed that in the chicken embryo model, the 258 
PhIP-induced inhibition of the neural cell differentiation of neural tube cells can be 259 
ameliorated by adding 5μM Nano-SFN. 260 
261 
 Figure 4 PhIP-induced inhibition of the neural cell differentiation of neural 262 
tube cells can be improved by adding Nano-SFN. (A) Immunofluorescence of NF 263 
in the neural cells of the chick embryos. White arrows indicate NF-positive cells (n = 264 
12 per group). (B) Bar chart comparing the ratios of the positive neural cells among 265 
the different treatment groups. **p<0.01. Scale bars = 50µm (A). 266 
 267 
3.4. Nano-SFN improved PhIP-suppressed NCCs generation and migration 268 
Ap2α immunofluorescence was used to characterize cranial neural crest cells 269 
(CNCCs) (Figure 5A; the expression is represented by the white area, and the white 270 
arrows indicate the sections), and the effects in the control, 200μM PhIP and 200μM 271 
PhIP + 5μM Nano-SFN groups on the CNCCs in the chicken embryos were detected. 272 
The results showed that CNCCs were significantly decreased after the treatment with 273 
200μM PhIP, and the production of CNCCs returned to normal after 5μM Nano-SFN 274 
treatment (Control = 9.31 ± 1.69; 200μM PhIP = 6.54 ± 1.97; 200μM PhIP + 5μM 275 
Nano-SFN = 9.42 ± 0.84; Figure 5B). In addition, according to the specific staining of 276 
migrating NCCs with HNK1 (shown in the white area of Figure 5C), the HNK1 277 
expression area was decreased significantly by treatment with 200μM PhIP, and the 278 
HNK1-positive area increased significantly after the 200μM PhIP + 5μM Nano-SFN  279 
treatment (Control = 8.59 ± 2.02; 200μM PhIP = 4.04 ± 3.45; 200μM PhIP + 5μM 280 
Nano-SFN = 8.27 ± 2.75; Figure 5D). The experiment confirmed that in the chicken 281 
embryo model, the inhibition of NCCs production and migration by PhIP can be 282 
improved by adding Nano-SFN. 283 
 284 
Figure 5 Nano-SFN can ameliorate the inhibition by PhIP of NCCs production 285 
and migration. (A) Whole-mount immunofluorescence and transverse sections of the 286 
Ap2α in CNCCs. (B) Bar chart comparing the CNCC areas among the different 287 
treatment groups. (C) Representative images of migratory NCCs stained with HNK1 288 
as indicated by the dotted squares. (D) Bar chart comparing migrating NCC areas 289 
among the different treatment groups. **p<0.01. Scale bars = 100µm (whole-mount); 290 
50μm (section). n = 18 (B), 41 (D). 291 
 292 
3.5. Nano-SFN ameliorated PhIP-induced neural tube cell apoptosis and inhibition of 293 
neural tube cell proliferation 294 
We cultured chicken embryos to HH10 and labeled the proliferating cells on the 295 
neural tube with pHH3 (Figure 6A). The results showed that the number of 296 
pHH3-positive cells decreased significantly under 200μM PhIP treatment, while 297 
following 200μM PhIP + 5μM Nano-SFN treatment, the number of pHH3-positive 298 
cells returned to normal levels (Control = 13 ± 3.03; 200μM PhIP = 5.07 ± 1.77; 299 
200μM PhIP + 5μM Nano-SFN = 12.71 ± 2.69; Figure 6B). At the same time, 300 
apoptotic cells in the neural tube were labelled with c-Caspase3 (Figure 6C), which 301 
showed that the number of c-Caspase3-positive cells increased significantly under 302 
200μM PhIP treatment. By contrast, the number of c-Caspase3-positive cells 303 
decreased significantly under 200μM PhIP + 5μM Nano-SFN treatment (Control = 304 
6.14 ± 1.95; 200μM PhIP = 18.46 ± 5.62; 200μM PhIP + 5μM Nano-SFN = 7.00 ± 305 
2.38; Figure 6D). The experiments confirmed that Nano-SFN could significantly 306 
ameliorate PhIP-induced neural tube cell apoptosis and inhibition of neural tube cell 307 
proliferation in the chicken embryo model. 308 
309 
Figure 6 Nano-SFN ameliorated PhIP-induced apoptosis and inhibition of the 310 
proliferation of embryonic neural tube cells. (A) The merged images from the 311 
pHH3+ and DAPI staining of the chick embryo neural tubes, with pHH3+ cells 312 
indicated by the white arrows. (B) Bar chart comparing the proliferating cell areas 313 
from the chick embryo neural tube among the different treatment groups. (C) 314 
Representative images of chick embryo neural tube apoptotic cells stained with 315 
c-Caspase3 as indicated by the white arrows. (D) Bar chart comparing the apoptotic 316 
cell areas among the different treatment groups. ***p<0.001. n = 27 per group (B) 317 
and (D). Scale bar = 50μm (A) and (C). 318 
4. Discussion 319 
A number of recent studies have demonstrated great potential of nanotechnology 320 
in the diagnosis and treatment of various human diseases in biomedicine (Kinnear et 321 
al., 2017). Meanwhile, there’re many articles indicating that biological 322 
nanotechnology is one of the most intruiging fields in nanoscience applications. In 323 
recent decades, the applications of nanotechnology in a number of biology-related 324 
fields—such as diagnostics, drug delivery and molecular imaging—have been 325 
thoroughly researched, with excellent results. However, the most significant advances 326 
in nanotechnology belong to the field of biomedicine, in which they possess a huge 327 
potential to provide innovative solutions. With the advancement of modern science, it 328 
is becoming more and more feasible to design targeted or multifunctional 329 
nanotechnology products for therapeutic applications. There are many parameters that 330 
are important for the successful development and manufacture of targeted drug 331 
delivery vehicles. The efficacy of nanoparticles as a vehicle is highly dependent on 332 
both size and shape (Navya, P.N., 2019). The size of the nanoparticles affects their 333 
movement into and out of the blood vessels, and the particle at the edge of the blood 334 
vessel wall is affected by its shape (Farokhzad et al., 2009). As shown in  the figure, 335 
the Nano-SFN we made are nearly spherical, with a uniform particle size; the particle 336 
size is 195 ± 32 nm, and the particle distribution is relatively uniform (Figure 2). 337 
Therefore, Nano-SFN prepared by our method could easily enter and exit blood 338 
vessels, as well as pass through the placental barrier and be suitable for absorption in 339 
the human body. 340 
Neural development involves a series of coordinated morphological events that 341 
cause the flat nerve plate to turn into a neural tube, the primordium base of the entire 342 
CNS (Copp et al., 2003). NTDs can lead to severe abnormalities of the CNS, which 343 
are one of the most common congenital malformations in humans (Sanna et al., 2019). 344 
PhIP has been shown to have a negative effect on early embryonic development. In 345 
this study, the effect of PhIP’s experimental concentration on neurotoxicity and the 346 
embryo survival rate was studied. Embryo mortality in the experimental groups of our 347 
study was the highest in the 200μM PhIP group in terms of the median lethal dose 348 
(LD50) and neural tube malformation rates. Therefore, 200μM PhIP was selected for 349 
the treatment group, and a 5μM Nano-SFN intervention was chosen based on existing 350 
literature (G. Wang et al., 2018). The results showed that Nano-SFN reduced 351 
PhIP-induced embryonic death and NTDs.  352 
Neural tube closure has been studied for many decades. We can easily observe 353 
the NTDs using the Pax7 immunofluorescence (Figure 3). However, Pax7 does have 354 
systemic expression on embryos including neural tube and somites. The malformation 355 
of somites also can be found, which suggested that PhIP on embryonic development 356 
in general. In this study, our research only focused on neurogenesis because 357 
neurogenesis is one of the earliest processes that occur in embryonic development. 358 
NTDs is complex and involves cellular events. Proper differentiation, cell survival 359 
and neural crest migration are closely related to neural tube development 360 
(Nikolopoulou et al., 2017). Neurons can be determined by the NF protein (Regan, 361 
1988). We found that the PhIP-induced inhibition of the neural cell differentiation of 362 
neural tube cells could be reversed by adding 5μM Nano-SFN (Figure 4). The 363 
development of the nervous system is a complex process involving the induction, 364 
determination and movement of cells. NCCs are a pluripotent cell group with high 365 
migrative ability. The signaling of PNS elements is mediated by specific cell groups 366 
that originate from the top of the neural tube—that is, NCCs (Catala et al., 367 
2013)—and in the process of development, NCCs migrate normally to form the 368 
neurons and glial cells of the PNS, which are of great significance to the 369 
establishment of the embryonic nervous system (Giovannone et al., 2015). In our 370 
study, the application of AP2α (specifically expressed on CNCCs) and HNK-1 371 
(expressed on migrating NCCs) (Minarcik et al., 2003) allowed us to reveal that 372 
pre-migratory and migrating CNCCs were significantly affected by PhIP, and the 373 
addition of Nano-SFN could ameliorate the inhibition of NCCs production and 374 
migration by PhIP (Figure 5). 375 
Neurogenesis plays a key role in the neuroplasticity of the CNS, brain 376 
homeostasis and maintenance (Poulose et al., 2017); this process is a highly complex, 377 
multi-step process that begins with the proliferation of progenitor cells (Balu et al., 378 
2009). Orderly cell apoptosis also regulates normal processes in embryogenesis such 379 
as the fusion of the oral palate and neural tube and craniofacial development (Graham 380 
et al., 1993; Graham et al., 1996; Lawson et al., 1998; Weil et al., 1997). However, 381 
teratogenic factor-induced excess apoptosis is always involved in NTDs and NCCs 382 
developmental anomalies (Chappell et al., 2009; Torchinsky et al., 2005). In this paper, 383 
pHH3 and c-Caspase3 were used to label proliferating cells and apoptotic cells in the 384 
neural tube (Figure 6). Apoptosis is one of several integrated responses to DNA 385 
damage (J. Y. Wang, 2001). Nano-SFN might target PhIP-induced excessive DNA 386 
damage, which may, in turn, contributing to the protective effects on embryonic 387 
neurogenesis. 388 
This article mainly discusses the new application of Nano-SFN in the protection 389 
against embryonic nervous system dysplasia. The results show that Nano-SFN plays 390 
an important role in the formation of the CNS and PNS in the embryonic nervous 391 
system, indicating that Nano-SFN can effectively alleviate the PhIP 392 
microenvironment-induced abnormal development of the embryonic nervous system 393 
and has a protective effect on embryonic development. Based on our findings, the 394 
women at the early stage of pregnancy should avoid taking barbecue, instead, increase 395 
intake amount of cruciferous vegetables, which benefits the fetal neural development. 396 
The range of applications for SFN has been expanded, and the practical value of SFN 397 
has been improved, which provides the possibility of further developing new drugs. 398 
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